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Rosa M. Alvarez, SB,y Kenneth B. Margulies, MDzSEE PAGE 436C ardiovascular diseases, including myocardialinfarction and heart failure, remain the lead-ing causes of morbidity and mortality in the
developedworld. Because the loss of cardiac myocytes
contributes to most types of heart failure, strategies
designed to achieve therapeutic cardiac regeneration
are being aggressively sought. Since the ﬁrst report
in 2006 (1), the reﬁnement of methods for reprogram-
ming differentiated somatic cells into human-induced
pluripotent stem cells (iPSCs) with regenerative capac-
ity comparable to that of embryonic stem cells has
further energized basic inquiries into the factors
shaping cell fate and has fueled translational efforts
toward therapeutic cardiac regeneration.
Given that all of a person’s somatic cells have
essentially the same DNA sequence, it has been in-
creasingly appreciated that determination of cell fate
and phenotypic features is strongly affected by which
parts of the DNA sequence are available to regulate
gene expression. This availability for transcription is
largely controlled by so-called epigenetic modiﬁca-
tions, including DNA methylation and histone modi-
ﬁcations. In general, embryonic stem cells and iPSCs
have epigenetic modiﬁcations restricting lineage-
speciﬁc gene expression and thus are pluripo-
tent. Conversely, somatic cells have epigenetic marks
that restrict expression of some genes involved in
maintaining self-renewal or pluripotency, and this
contributes to their cell type–speciﬁc biology. Thus,* Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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entails reversing the process of cell differentiation
through tissue-speciﬁc epigenetic modiﬁcations and
re-establishing an embryonic epigenome, which can
include alterations in chromatin chemistry and struc-
ture and/or methylation of cytosine residues in DNA.
It has been shown that iPSCs can be generated froma
wide variety of somatic cells (2,3), but distinctions
among iPSCs generated from alternative cell types are
still being deﬁned. For example, studies diverge on
whether iPSCs derived from a somatic source retain
“epigenetic memory” and exhibit a preference for
differentiation into their original cell lineages. One
study reported an increased ability to differentiate
into insulin-producing beta cells when human pan-
creatic beta cells were used to derive iPSCs, compared
with beta cells derived from embryonic stem cells or
alternate iPSC sources (4). In another study, when
iPSCs were generated from bone marrow stromal cells
and dermal ﬁbroblasts from the same donor, cell type–
speciﬁc genes were equally silenced when they were
reprogrammed into iPSCs. However, gene expression
differences in iPSC clones from a single cell type were
greater than the differences observed between the 2
cell types (5). Notably, continuous passaging of iPSCs
largely attenuates these differences.In this issue of the Journal, Sanchez-Freire et al. (6)
report comparisons of 2 different iPSC sources from
the same donor: skin ﬁbroblasts and cardiac-derived
progenitor cells (CPCs) expressing the surface marker
Sca1. Using uniform protocols for both iPSC induction
and subsequent cardiac myocyte differentiation,
these investigators compared the yield and functional
characteristics of cardiac myocytes originating from
Sca1þ CPCs (CPC-iPSC-CMs) and dermal ﬁbroblasts
(Fib-iPSC-CMs) from 2 fetal donors and 1 adult donor.
The major distinctions observed were higher rates of
cardiac myocyte differentiation and early activation of
the cardiac transcription factor Nkx 2.5 and other
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450myogenic transcription factors using the CPCs as
the somatic cell source, as opposed to greater DNA
methylation of the Nkx 2.5 promoter when skin
ﬁbroblasts were used as the somatic cell source. The
investigators suggest that the reduced cardiac myo-
cyte differentiation efﬁciency of ﬁbroblast-derived
iPSCs results from epigenetic memory, such as the
persistent DNA methylation and consequent reduced
expression of the Nkx 2.5 gene. These investigators
found that CPC-derived iPSCs also differentiate
into endothelial cells and smooth muscle cells more
efﬁciently than do the ﬁbroblast-derived iPSCs.
Despite differences in efﬁciency of differentiation into
cardiac cell types, the investigators established that
cardiac myocytes derived indirectly from ﬁbroblasts
and CPCs are functionally equivalent in vitro, based on
electrophysiological and calcium (Ca2þ) handling
properties. They also demonstrated that CPC-iPSC-
CMs and Fib-iPSC-CMs have equivalent potential
for therapeutic efﬁcacy in vivo, based on similarly
improved cardiac function following cell delivery
to mouse hearts with experimental myocardial
infarction.
Despite the rigor of these studies, the number of
cases is small, and the data supporting a functional role
of Nkx 2.5 DNA methylation are correlative. Studies
relating speciﬁc manipulation of Nkx 2.5 methylation
status to cardiac cell differentiation efﬁciency would
be more compelling. Another shortcoming is the in-
trinsic difference in the cells selected from each loca-
tion: fully differentiated dermal ﬁbroblasts versus
multipotent CPCs. From this perspective, a compari-
son of dermal ﬁbroblasts with cardiac ﬁbroblasts
could allow more straightforward interpretation.
Nevertheless, these ﬁndings support the concept that
early-passage iPSCs retain epigenetic memory, which
manifests in differential gene expression and altered
differentiation capacity with preference to the cell
type of origin.The implications of these studies vary with one’s
view of the most promising therapeutic cardiac
myogenesis strategies. The functional equivalency of
Fib-iPSC-CMs and CPC-iPSC-CMs would favor using an
easily accessible somatic cell, such as dermal ﬁbro-
blasts or blood cells, for iPSC generation and delivery
to infarcted hearts. In this application, the lower efﬁ-
ciency of cardiac myocyte formation could be over-
come by greater passaging. An alternate vision of
therapeutic myogenesis for heart disease focuses on
direct reprogramming of somatic cells into functional
cardiomyocytes in situ without an iPSC intermediate.
Direct reprogramming of cardiac ﬁbroblasts in situ has
already been demonstrated in murine hearts by 2
separate laboratories (7,8). From this perspective, the
retained epigenetic memory of cardiac cells sug-
gested by Sanchez-Freire et al. (6) could enhance the
propensity for resident cardiac cells to transdiffer-
entiate into new cardiac myocytes following appro-
priate direct reprogramming agents. Of course, the
appreciation of epigenetic memory also suggests an
additional myogenic strategy: manipulation of adult
cardiac myocytes to allow transient re-entry into the
cell cycle and proliferationwhilemaintaining a cardiac
myocyte phenotype throughout the process (9,10).
Ultimately, further understanding of cell type–
speciﬁc epigenetic mechanisms in the regulation of
reprogramming, maintenance of pluripotency, and
induction of differentiation will be crucial for our
utilization of iPSC biology and the achievement of
therapeutic cardiac regeneration.
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